The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: Anti-angiogenic implications in pancreatic cancer

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages

  Patel, Mishaal B ^a   Pothula, Srinivasa P ^a   Xu, Zhihong ^a   Lee, Alexandra K ^a   Goldstein, David ^a   Pirola, Romano C ^a   Apte, Minoti V ^a   Wilson, Jeremy S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatocyte growth factor; Human microvascular endothelial cells; Pancreatic cancer; Pancreatic stellate cells; Stromal tumour interactions

Indexed keywords

ANGIOGENESIS INHIBITOR; HGF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UROKINASE;

APOPTOSIS; CELL COMMUNICATION; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATIC STELLATE CELL; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATOCYTE GROWTH FACTOR; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84905675342     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu122     Document Type: Article

References (53)

1. Maisonneuve, P. et al. (2010) Epidemiology of pancreatic cancer: an update. Dig Dis, 28(4-5):645-56.
2. Yadav, D. et al. (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology, 144(6):1252-61.
3. Pandol, S. et al. (2012) Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol, 27 Suppl 2:127-34.
4. Lowery, F.J. et al. (2012) Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Rev, 31(3-4):479-91.
5. Vonlaufen, A. et al. (2010) Isolation of quiescent human pancreatic stellate cells: a promising in vitro tool for studies of human pancreatic stellate cell biology. Pancreatology, 10(4):434-43.
6. Lunardi, S. et al. (2013) The stromal compartments in pancreatic cancer: Are there any therapeutic targets? Cancer Lett.
7. Yachida, S. et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319):1114-7.
8. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144(5):646-74.
9. Vonlaufen, A. et al. (2008) Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res, 68(7):2085-93.
10. Xu, Z. et al. (2010) Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol, 177(5):2585-96.
11. Tahara, H. et al. (2013) Transforming growth factor-alpha activates pancreatic stellate cells and may be involved in matrix metalloproteinase-1 upregulation. Lab Invest, 93(6):720-32.
12. Apte, M.V. et al. (2013) A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology, 144(6):1210-9.
13. Yen, B.L. et al. (2013) Multipotent Human Mesenchymal Stromal Cells Mediate Expansion of Myeloid-Derived Suppressor Cells via Hepatocyte Growth Factor/c- Met and STAT3. Stem Cell Reports, 1(2):139-51.
14. Matsumura, A. et al. (2013) HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol, 42(2):535-42.
15. McCarroll, J.A. et al. (2004) Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase(PI3-kinase) pathway. Biochem Pharmacol, 67(6):1215-25.
16. Nakamura, T. et al. (2011) Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol, 26 Suppl 1:188-202.
17. Birchmeier, C. et al. (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol, 8(10):404-10.
18. Kemik, O. et al. (2009) Increase in the circulating level of hepatocyte growth factor in pancreatic cancer patients. Bratisl Lek Listy, 110(10):627-9.
19. Ding, S. et al. (2003) HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood, 101(12):4816-22.
20. Kammula, U.S. et al. (2007) Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett, 248(2):219-28.
21. Grant, D.S. et al. (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A, 90(5):1937-41.
22. Lin, Y.M. et al. (2012) Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One, 7(11):e50924.
23. Xin, X. et al. (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol, 158(3):1111-20.
24. Mignatti, P. et al. (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein, 49(1-3):117-37.
25. Li, H. et al. (2013) uPA and MMP-2 were involved in self-assembled network formation in a two dimensional co-culture model of bone marrow stromal cells and endothelial cells. J Cell Biochem, 114(3):650-7.
26. Hildenbrand, R. et al. (2009) Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol, 174(6):2246-53.
27. Sorio, C. et al. (2011) Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer, 11:448.
28. Naldini, L. et al. (1992) Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J, 11(13):4825-33.
29. Bauer, T.W. et al. (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res, 65(17):7775-81.
30. Bachem, M.G. et al. (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology, 115(2):421-32.
31. Apte, M.V. et al. (1998) Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut, 43(1):128-33.
32. Pothula, S. et al. (2013) Hepatocyte growth factor inhibition: a therapeutic approach superior to gemcitabine in pancreatic cancer? Pancreas, 42(1377).
33. Burgess, T.L. et al. (2010) Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther, 9(2):400-9.
34. Christensen, J.G. et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res, 63(21):7345-55.
35. Arnaoutova, I. et al. (2009) The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis, 12(3):267-74.
36. Hill, K.S. et al. (2012) Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One, 7(7):e40420.
37. Naldini, L. et al. (1995) Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem, 270(2):603-11.
38. Erkan, M. et al. (2009) Cancer-stellate cell interactions perpetuate the hypoxiafibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia, 11(5):497-508.
39. Masamune, A. et al. (2008) Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol, 295(4):G709-17.
40. Matthews, H. et al. (2011) Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorg Med Chem Lett, 21(22):6760-6.
41. Nakagami, H. et al. (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension, 37(2 Pt 2):581-6.
42. Li, Y. et al. (2013) Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling. Mol Cell Biochem, 382(1-2):83- 92.
43. Paoli, P. et al. (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta.
44. Boccaccio, C. et al. (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 391(6664):285-8.
45. Mankal, P. et al. (2013) Sunitinib malate for the treatment of pancreas malignancies - where does it fit? Expert Opin Pharmacother.
46. Goel, S. et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev, 91(3):1071-121.
47. Paez-Ribes, M. et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15(3):220-31.
48. Ebos, J.M. et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15(3):232-9.
49. Tijeras-Raballand, A. et al. (2012) Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Target Oncol, 7(3):173-81.
50. Kindler, H.L. et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol, 28(22):3617-22.
51. Welti, J. et al. (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest, 123(8):3190-200.
52. Wen, P.Y. et al. (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol, 13(4):437-46.
53. Schoffski, P. et al. (2011) A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int, 108(5):679-86.